Power Targeted Therapeutic & Clinical Breakthroughs Across Different Autoimmune Cell Therapies with Proven Safety, Sustained Efficacy, & Greater Patient Access to Redefine Chronic Care of Autoimmune Diseases
Ever since cell therapies demonstrated potential in lupus and beyond, focus has shifted from oncology to advancing the first approved autoimmune cell therapy to market.
The 3rd Cell Therapy for Autoimmune Disease Summit returns at a transformative moment for this field, as autoimmune therapies stand poised to lead the next frontier of cell therapy innovation. As the only forum spotlighting breakthroughs across CAR-T, Treg, NK and in vivo cell therapies, this is your opportunity to gain end-to-end insights to navigate the dynamic, high-velocity road to market.
Uncover first-hand experiences from industry titans including Cabaletta Bio, Kyverna Therapeutics, Umoja Biopharma, Cartesian Therapeutics, Century Therapeutics, Artiva Biotherapeutics and Novartis, to accelerate your therapeutic progression and remain ahead of your peers.
From target selection and IND preparation to clinical trial design, patient recruitment, and long-term data, this year’s edition will empower you to translate clinical promise into real breakthroughs.
This summit was extremely informative and collaborative. There were plenty of opportunities to network and engage in diverse sessions, spanning basic and clinical science
Vice President, Cullinan Therapeutics, Past Attendee
The World-Class Speaker Faculty:
Who Could You Meet?
Proud to Partner With:
The meeting last year was outstanding as a way to keep abreast of this fast-moving space in a very collegial environment
Chief Executive Officer, iCellGene Therapeutics, Past Attendee
It was very nice to have active leaders in the CAR-T space share their learnings and challenges in an open forum with an emphasis on collaboration
Associate Director, TG Therapeutics, Past Attendee
